For glaucoma patients, taking daily medication will soon become a thing of the past.
Instead, with Nanyang Technological University's (NTU) newest solution, a simple, quick and painless injection four times a year would be enough.
The solution contains an anti-glaucoma drug wrapped in nano-sized capsules, and is delivered by an injection into the outer layer in the front of the eye (conjunctiva) by the doctor.
The nanocarrier will then slowly release the drug over several weeks. LipoLat, as it is known, is now ready for clinical trials.
Extensive pre-clinical studies have shown that this single injection is as effective at treating glaucoma as taking daily eye drops for up to 3 months.
Forgetting to administer the daily eye drops is the most common problem faced by glaucoma sufferers, and failure in taking the eyedrops correctly on a daily basis can result in a tragic and permanent loss of vision.
There are also many problems with eye drops, including allergies, unpleasant side effects, remembering to take them at the correct time, correct insertion technique, storage and hygiene.
Such an innovative 'eye-dea' like LipoLat is what NTU's latest research centre launched today - Ocular Therapeutic Engineering Centre - has as its mission.
Housed at NTU's School of Materials Science and Engineering, OTEC builds upon the School's successful research collaboration with the Singapore Eye Research Institute.
Centre Director, Professor Subbu Venkatraman, who is also the School Chair, said the centre will build on the strong research collaboration between clinical scientists and NTU technologists, to develop new drug delivery systems for the eye.
"I hope to showcase this as a good example of how close interactions between medical practitioners and technology providers can lead to rapid translation of ideas to the clinic, such as LipoLat," said Prof Venkatraman. "We are confident t
|Contact: Lester Kok|
Nanyang Technological University